Adage Capital Partners’s Cogent Biosciences COGT Stock Holding History

Adage Capital Partners’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.92M	Sell	50,000 -50,000	-50%	-$1.85M	﹤0.01%	839
2025 Q4	$3.55M	Sell	100,000 -462,000	-82%	-$13M	0.01%	794
2025 Q3	$8.07M	Buy	+562,000	New	+$6.66M	0.01%	670
2025 Q1	–	Sell	-4,300,000	Closed	-$33.5M	–	863
2024 Q4	$33.5M	Buy	4,300,000 +233,966	+6%	+$2.33M	0.06%	304
2024 Q3	$43.9M	Sell	4,066,034 -182,854	-4%	-$1.78M	0.08%	254
2024 Q2	$35.8M	Buy	4,248,888 +2,915,555	+219%	+$22.1M	0.07%	290
2024 Q1	$8.96M	Buy	+1,333,333	New	+$8.24M	0.02%	619
2023 Q4	–	Sell	-1,036,069	Closed	-$10.1M	–	872
2023 Q3	$10.1M	Sell	1,036,069 -100,000	-9%	-$1.19M	0.02%	559
2023 Q2	$13.5M	Sell	1,136,069 -250,544	-18%	-$2.87M	0.03%	508
2023 Q1	$15M	Buy	1,386,613 +350,000	+34%	+$4.48M	0.03%	510
2022 Q4	$12M	Sell	1,036,613 -110,037	-10%	-$1.36M	0.03%	592
2022 Q3	$17.1M	Sell	1,146,650 -80,000	-7%	-$1.1M	0.04%	470
2022 Q2	$11.1M	Buy	+1,226,650	New	+$8.37M	0.03%	645

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners's COGT Position: Q1 2026 in Review

Adage Capital Partners reduced its Cogent Biosciences (COGT) stake by 50% in Q1 2026, selling an estimated $1.85M and leaving 50,000 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #839.

Adage Capital Partners first reported a position in COGT in Q2 2022 and has held it in 13 quarters since. The position peaked at $43.9M in Q3 2024. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

Adage Capital Partners held 50,000 shares of Cogent Biosciences worth $1.92M as of Q1 2026.
Adage Capital Partners sold 50,000 Cogent Biosciences shares in Q1 2026, an estimated $1.85M.
Cogent Biosciences made up ﹤0.01% of Adage Capital Partners's portfolio in Q1 2026, its #839 holding.
Adage Capital Partners first reported a position in Cogent Biosciences in Q2 2022 and has held it in 13 quarters since.
Adage Capital Partners's Cogent Biosciences position peaked at $43.9M in Q3 2024.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.